Published in Clin Infect Dis on October 17, 2006
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Which policy to ADAP-T: waiting lists or waiting lines? Clin Infect Dis (2006) 1.16
Current challenges to the United states' AIDS drug assistance program and possible implications of the affordable care act. AIDS Res Treat (2013) 1.08
Improving outcomes in state AIDS drug assistance programs. J Acquir Immune Defic Syndr (2009) 0.96
Understanding HIV care delays in the US South and the role of the social-level in HIV care engagement/retention: a qualitative study. Int J Equity Health (2014) 0.88
Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One (2013) 0.78
Translating the A1C assay into estimated average glucose values. Diabetes Care (2008) 11.55
The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res (2004) 10.47
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res (2004) 6.04
MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell (2011) 5.91
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
[Human natural infection of Plasmodium knowlesi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2006) 3.99
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A (2004) 2.99
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Dimorphic effects of Notch signaling in bone homeostasis. Nat Med (2008) 2.82
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis (2009) 2.62
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Perpetration of intimate partner violence associated with sexual risk behaviors among young adult men. Am J Public Health (2006) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell (2002) 2.37
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis (2009) 2.33
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res (2003) 2.32
Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med (2002) 2.30
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A (2002) 2.29
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol (2009) 2.23
Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci (2005) 2.21